Developer docs
API playgroundTry for free, no card

Search company profiles

Artelo Biosciences

Full company profile

uuid0000ixm

Namestring
Artelo Biosciences
Legal namestring
Artelo Biosciences, Inc.
Websiteurl
artelobio.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Artelo Biosciences is a clinical-stage biopharmaceutical company developing a portfolio of three drug candidates that modulate lipid-signaling pathways, founded in 2017 and headquartered in Solana Beach, California, with a wholly-owned UK subsidiary in Alderley Park. The company targets serious conditions with limited or no approved treatments: ART27.13 is a peripherally restricted synthetic dual CB1/CB2 cannabinoid receptor agonist in Phase 1/2 development for cancer anorexia-cachexia syndrome (CAReS trial across 18 sites in 5 countries), with additional investigator-sponsored programs in glaucoma and a provisional patent for GLP-1 muscle preservation; ART26.12 is the first selective Fatty Acid Binding Protein 5 (FABP5) inhibitor to enter human trials, being developed as a non-opioid analgesic for chemotherapy-induced peripheral neuropathy and other neuropathic and inflammatory conditions; and ART12.11 is a proprietary CBD:tetramethylpyrazine cocrystal with composition-of-matter protection through December 2038, in preclinical development for anxiety and depression.

The business model is pre-revenue: Artelo has no commercial products, no FDA approvals, and no recurring revenue streams, with FY2025 net loss of $12.9 million and only $0.6 million in cash and investments at year-end. Capital is raised through dilutive equity instruments — five public offerings and private placements between June 2025 and May 2026 totaling approximately $32 million plus warrant potential, a $25 million equity access facility, and an unusual Solana cryptocurrency treasury strategy — rather than through product sales. Go-to-market is structured around investigator-sponsored studies and clinical-trial supply rather than commercial sales infrastructure, with the company employing only seven full-time staff. Management indicates ongoing unsolicited partnership discussions with global pharmaceutical companies, suggesting the eventual commercial pathway will likely involve out-licensing or co-development rather than independent launch.

Customer-facing activity is restricted to clinical trial operations across academic medical centers (Queen's University Belfast, Belfast HSC Trust) and a research collaboration with the AI firm ScienceMachine. Marketing and communications are concentrated in investor relations, peer-reviewed scientific publications, and conference presentations rather than physician or patient promotion, consistent with a pre-commercial clinical-stage organization.

Short descriptiontext

Artelo Biosciences is a clinical-stage biopharmaceutical company developing lipid-signaling therapeutics — including the dual cannabinoid receptor agonist ART27.13, FABP5 inhibitor ART26.12, and CBD cocrystal ART12.11 — for cancer cachexia, neuropathic pain, and CNS disorders, with no approved products and revenue generated solely through dilutive financings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLa Jolla, United States
HQ citystring
La Jolla
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceuticals, endocannabinoid therapeutics, lipid-signaling modulation, FABP inhibitors, cannabinoid receptor agonists
Industry3 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAAAAAI
Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Analytical Laboratory Instrument Manufacturing334516
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Medicinal Chemicals & Botanical Products2833
Product category
Clinical-stage Biopharmaceutical Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1No Commercial Revenue
TypeSubscription Recurring
Description

Artelo Biosciences is a clinical-stage biopharmaceutical company with no commercial products. The company currently has no product revenue and is focused on developing its pipeline of drug candidates through clinical trials. All revenue-related activity consists of raising capital through equity financings.

artelobio.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Artelo Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of three drug candidates that modulate lipid-signaling pathways and the endocannabinoid system. The pipeline includes ART27.13 (dual CB1/CB2 receptor agonist for cancer anorexia-cachexia syndrome), ART26.12 (selective FABP5 inhibitor for chemotherapy-induced peripheral neuropathy and neuropathic pain), and ART12.11 (CBD:TMP cocrystal for anxiety and depression). The company has no commercial products and currently generates no product revenue.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 64% of patients (14/22) reported weight stabilization or weight gain at day 28 in Phase 1 CAReS trial
+4 more records
Product overview1 text field

Artelo Biosciences is a clinical-stage biopharmaceutical company developing a portfolio of three distinct drug candidates targeting lipid-signaling pathways. The pipeline consists of: ART27.13 (dual cannabinoid receptor agonist for cancer anorexia-cachexia), ART26.12 (FABP5 inhibitor for neuropathic pain and cancer), and ART12.11 (CBD-based cocrystal for anxiety and depression). The company is currently conducting Phase 1/2 clinical trials for ART27.13 and ART26.12, with ART12.11 in preclinical development.

Product and service3 records
1ART27.13
CategoryClinical-stage drug candidate
Description

ART27.13 is a peripherally restricted, orally administered, synthetic dual cannabinoid receptor (CB1 and CB2) agonist developed as a first-in-class treatment for cancer anorexia-cachexia syndrome (CACS) and explored for muscle preservation in GLP-1 therapy and glaucoma. It is structurally distinct from phytocannabinoids like THC to avoid controlled substance scheduling. Currently in Phase 1/2 clinical trials (CAReS study).

2ART26.12
CategoryClinical-stage drug candidate
Description

ART26.12 is a potent and selective Fatty Acid Binding Protein 5 (FABP5) inhibitor being developed as a peripherally acting, non-opioid, non-steroidal analgesic for chemotherapy-induced peripheral neuropathy (CIPN), other neuropathic pain, psoriasis, and certain cancers. Phase 1 results showed all adverse events were mild, transient, and self-resolving.

3ART12.11
CategoryClinical-stage drug candidate
Description

ART12.11 is a proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP) designed to improve bioavailability and pharmacokinetics of CBD compared to other forms of CBD in preclinical models. It is being developed for the treatment of anxiety and depression.

Scale indicator17 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-25
Description

Academic partnership for ART27.13 development in glaucoma market expansion, working in conjunction with Glaucoma UK and HSC R&D Division.

2Belfast Health and Social Care Trust
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-18
Description

Investigator-sponsored clinical study evaluating ART27.13 (peripherally selective synthetic cannabinoid) in patients with glaucoma or ocular hypertension. First patient enrollment anticipated in Q2 2026. Artelo will supply ART27.13 capsules as Investigational Medicinal Product.

globenewswire.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Attracted unsolicited partnership interest from global pharmaceutical companies. Discussions ongoing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-05
Description

Academic medical center partnership for CAReS (Cancer Appetite Recovery Study) Phase 1/2 trial evaluating ART27.13 in cancer anorexia-cachexia syndrome with 18 sites across 5 countries.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-01-01
Description

Strategic AI partnership to accelerate development of FABP5 inhibitor platform using ScienceMachine's AI agent technology. Since collaboration began in 2025, ScienceMachine has analyzed Artelo's biological datasets, identifying potential proteins indicative of FABP5 target engagement in healthy volunteers and novel protein and lipid signatures correlated with ART26.12's analgesic effect. Preliminary results from psoriasis model study planned for publication later in 2026.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Corbus develops cannabinoid receptor-targeting drug candidates for inflammatory and fibrotic diseases, sharing Artelo's strategy of modulating endocannabinoid system pathways for serious conditions with limited treatment options.

TypeBroad incumbent
Description

Jazz (via GW Pharma) pioneered FDA-approved cannabinoid therapeutics (e.g., Epidiolex) and is the broad incumbent against which all small cannabinoid-modulating biopharmas — including Artelo — are benchmarked.

3Botanix Pharmaceuticals
TypeDirect peer
Description

Botanix develops CBD-based therapeutics for dermatology indications including psoriasis, overlapping directly with Artelo's ART26.12 psoriasis program and Artelo's CBD-cocrystal technology.

TypeEmerging player
Description

Cara's peripherally restricted kappa opioid receptor agonist (difelikefalin/Korsuva) shares Artelo's design principle of peripheral selectivity to limit CNS side effects, making its clinical/commercial playbook highly relevant to ART27.13.

5Tetra Bio-Pharma
TypeEmerging player
Description

Tetra develops cannabinoid-derived therapeutics for pain, oncology supportive care, and inflammatory conditions, overlapping Artelo's ART27.13 (cancer cachexia) and ART26.12 (neuropathic pain) indications.

TypeDirect peer
Description

InMed is a clinical-stage pharmaceutical company developing cannabinoid-based therapeutics (including rare-disease and dermatology indications), directly comparable to Artelo's CBD:TMP cocrystal (ART12.11) and broader cannabinoid pipeline.

TypeDirect peer
Description

Zynerba develops transdermal CBD therapies for CNS-related conditions including Fragile X and 22q deletion syndromes; its percutaneous delivery and CBD-focused pipeline is comparable to Artelo's ART12.11 CBD:TMP cocrystal approach for CNS indications.

TypeEmerging player
Description

Anebulo is an early-stage clinical company developing cannabinoid receptor modulators for intoxication and substance-use disorders, sharing Artelo's science platform around selective cannabinoid receptor targeting.

TypeEmerging player
Description

Sol-Gel is a dermatology-focused specialty pharmaceutical company developing topical treatments for inflammatory skin diseases including psoriasis, comparable to Artelo's ART26.12 psoriasis development pathway.

TypeDirect peer
Description

Skye Bioscience is developing cannabinoid-derived therapeutics, including a CB1-receptor-targeting candidate for glaucoma, making it the most directly comparable peer to Artelo's ART27.13 in glaucoma and to Artelo's broader cannabinoid receptor agonist platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Artelo Biosciences

Clinical-stage Biopharmaceutical Therapeuticsartelobio.com

Artelo Biosciences is a clinical-stage biopharmaceutical company developing lipid-signaling therapeutics — including the dual cannabinoid receptor agonist ART27.13, FABP5 inhibitor ART26.12, and CBD cocrystal ART12.11 — for cancer cachexia, neuropathic pain, and CNS disorders, with no approved products and revenue generated solely through dilutive financings.

What Artelo Biosciences does

Artelo Biosciences is a clinical-stage biopharmaceutical company developing a portfolio of three drug candidates that modulate lipid-signaling pathways, founded in 2017 and headquartered in Solana Beach, California, with a wholly-owned UK subsidiary in Alderley Park. The company targets serious conditions with limited or no approved treatments: ART27.13 is a peripherally restricted synthetic dual CB1/CB2 cannabinoid receptor agonist in Phase 1/2 development for cancer anorexia-cachexia syndrome (CAReS trial across 18 sites in 5 countries), with additional investigator-sponsored programs in glaucoma and a provisional patent for GLP-1 muscle preservation; ART26.12 is the first selective Fatty Acid Binding Protein 5 (FABP5) inhibitor to enter human trials, being developed as a non-opioid analgesic for chemotherapy-induced peripheral neuropathy and other neuropathic and inflammatory conditions; and ART12.11 is a proprietary CBD:tetramethylpyrazine cocrystal with composition-of-matter protection through December 2038, in preclinical development for anxiety and depression.

The business model is pre-revenue: Artelo has no commercial products, no FDA approvals, and no recurring revenue streams, with FY2025 net loss of $12.9 million and only $0.6 million in cash and investments at year-end. Capital is raised through dilutive equity instruments — five public offerings and private placements between June 2025 and May 2026 totaling approximately $32 million plus warrant potential, a $25 million equity access facility, and an unusual Solana cryptocurrency treasury strategy — rather than through product sales. Go-to-market is structured around investigator-sponsored studies and clinical-trial supply rather than commercial sales infrastructure, with the company employing only seven full-time staff. Management indicates ongoing unsolicited partnership discussions with global pharmaceutical companies, suggesting the eventual commercial pathway will likely involve out-licensing or co-development rather than independent launch.

Customer-facing activity is restricted to clinical trial operations across academic medical centers (Queen's University Belfast, Belfast HSC Trust) and a research collaboration with the AI firm ScienceMachine. Marketing and communications are concentrated in investor relations, peer-reviewed scientific publications, and conference presentations rather than physician or patient promotion, consistent with a pre-commercial clinical-stage organization.

Artelo Biosciences firmographics

Firmographics
Name
Artelo Biosciences
Legal name
Artelo Biosciences, Inc.
Website
https://artelobio.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Artelo Biosciences is a clinical-stage biopharmaceutical company developing lipid-signaling therapeutics — including the dual cannabinoid receptor agonist ART27.13, FABP5 inhibitor ART26.12, and CBD cocrystal ART12.11 — for cancer cachexia, neuropathic pain, and CNS disorders, with no approved products and revenue generated solely through dilutive financings.
Ownership category
akta.pro rank

Artelo Biosciences industry classification

Industry
Product category
Clinical-stage Biopharmaceutical Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAAAAAI
Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Clinical-stage biopharmaceuticals
  • Endocannabinoid therapeutics
  • Lipid-signaling modulation
  • FABP inhibitors
  • Cannabinoid receptor agonists

Where Artelo Biosciences is headquartered

Location

Headquarters

HQ city
La Jolla
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Artelo Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. No Commercial Revenue: Artelo Biosciences is a clinical-stage biopharmaceutical company with no commercial products. The company currently has no product revenue and is focused on developing its pipeline of drug candidates through clinical trials. All revenue-related activity consists of raising capital through equity financings.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Artelo Biosciences product offering

Product offering

Core offering

Artelo Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of three drug candidates that modulate lipid-signaling pathways and the endocannabinoid system. The pipeline includes ART27.13 (dual CB1/CB2 receptor agonist for cancer anorexia-cachexia syndrome), ART26.12 (selective FABP5 inhibitor for chemotherapy-induced peripheral neuropathy and neuropathic pain), and ART12.11 (CBD:TMP cocrystal for anxiety and depression). The company has no commercial products and currently generates no product revenue.

Product overview

Artelo Biosciences is a clinical-stage biopharmaceutical company developing a portfolio of three distinct drug candidates targeting lipid-signaling pathways. The pipeline consists of: ART27.13 (dual cannabinoid receptor agonist for cancer anorexia-cachexia), ART26.12 (FABP5 inhibitor for neuropathic pain and cancer), and ART12.11 (CBD-based cocrystal for anxiety and depression). The company is currently conducting Phase 1/2 clinical trials for ART27.13 and ART26.12, with ART12.11 in preclinical development.

Differentiator

Problem solved

Functional benefit

Products and services

  • ART27.13 ART27.13 is a peripherally restricted, orally administered, synthetic dual cannabinoid receptor (CB1 and CB2) agonist developed as a first-in-class treatment for cancer anorexia-cachexia syndrome (CACS) and explored for muscle preservation in GLP-1 therapy and glaucoma. It is structurally distinct from phytocannabinoids like THC to avoid controlled substance scheduling. Currently in Phase 1/2 clinical trials (CAReS study).
  • ART26.12 ART26.12 is a potent and selective Fatty Acid Binding Protein 5 (FABP5) inhibitor being developed as a peripherally acting, non-opioid, non-steroidal analgesic for chemotherapy-induced peripheral neuropathy (CIPN), other neuropathic pain, psoriasis, and certain cancers. Phase 1 results showed all adverse events were mild, transient, and self-resolving.
  • ART12.11 ART12.11 is a proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP) designed to improve bioavailability and pharmacokinetics of CBD compared to other forms of CBD in preclinical models. It is being developed for the treatment of anxiety and depression.

Quantifiable outcome

  • 64% of patients (14/22) reported weight stabilization or weight gain at day 28 in Phase 1 CAReS trial
  • +4 more outcomes

Companies that use Artelo Biosciences

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Artelo Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Artelo Biosciences partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Queen's University BelfastcoreStrategic or Co-development Partner · 25 March 2026Academic partnership for ART27.13 development in glaucoma market expansion, working in conjunction with Glaucoma UK and HSC R&D Division.
  • Belfast Health and Social Care TrustcoreStrategic or Co-development Partner · 18 March 2026Investigator-sponsored clinical study evaluating ART27.13 (peripherally selective synthetic cannabinoid) in patients with glaucoma or ocular hypertension. First patient enrollment anticipated in Q2 2026. Artelo will supply ART27.13 capsules as Investigational Medicinal Product.
  • Global Pharmaceutical Companies (Unsolicited)minorStrategic or Co-development Partner · 1 January 2026Attracted unsolicited partnership interest from global pharmaceutical companies. Discussions ongoing.
  • Queen's University Belfast (CAReS)coreStrategic or Co-development Partner · 5 September 2025Academic medical center partnership for CAReS (Cancer Appetite Recovery Study) Phase 1/2 trial evaluating ART27.13 in cancer anorexia-cachexia syndrome with 18 sites across 5 countries.
  • ScienceMachinecoreTechnology or Integration · 1 January 2025Strategic AI partnership to accelerate development of FABP5 inhibitor platform using ScienceMachine's AI agent technology. Since collaboration began in 2025, ScienceMachine has analyzed Artelo's biological datasets, identifying potential proteins indicative of FABP5 target engagement in healthy volunteers and novel protein and lipid signatures correlated with ART26.12's analgesic effect. Preliminary results from psoriasis model study planned for publication later in 2026.

Scale indicators17 records

Recent moves6 records

Expansion highlights6 records

Artelo Biosciences competitors and assessment

Company assessment

Direct peers

  • Corbus Pharmaceuticals: Corbus develops cannabinoid receptor-targeting drug candidates for inflammatory and fibrotic diseases, sharing Artelo's strategy of modulating endocannabinoid system pathways for serious conditions with limited treatment options.
  • Botanix Pharmaceuticals: Botanix develops CBD-based therapeutics for dermatology indications including psoriasis, overlapping directly with Artelo's ART26.12 psoriasis program and Artelo's CBD-cocrystal technology.
  • InMed Pharmaceuticals: InMed is a clinical-stage pharmaceutical company developing cannabinoid-based therapeutics (including rare-disease and dermatology indications), directly comparable to Artelo's CBD:TMP cocrystal (ART12.11) and broader cannabinoid pipeline.
  • Zynerba Pharmaceuticals: Zynerba develops transdermal CBD therapies for CNS-related conditions including Fragile X and 22q deletion syndromes; its percutaneous delivery and CBD-focused pipeline is comparable to Artelo's ART12.11 CBD:TMP cocrystal approach for CNS indications.
  • Skye Bioscience: Skye Bioscience is developing cannabinoid-derived therapeutics, including a CB1-receptor-targeting candidate for glaucoma, making it the most directly comparable peer to Artelo's ART27.13 in glaucoma and to Artelo's broader cannabinoid receptor agonist platform.

Broad incumbents

  • Jazz Pharmaceuticals (GW Pharmaceuticals): Jazz (via GW Pharma) pioneered FDA-approved cannabinoid therapeutics (e.g., Epidiolex) and is the broad incumbent against which all small cannabinoid-modulating biopharmas — including Artelo — are benchmarked.

Emerging players

  • Cara Therapeutics: Cara's peripherally restricted kappa opioid receptor agonist (difelikefalin/Korsuva) shares Artelo's design principle of peripheral selectivity to limit CNS side effects, making its clinical/commercial playbook highly relevant to ART27.13.
  • Tetra Bio-Pharma: Tetra develops cannabinoid-derived therapeutics for pain, oncology supportive care, and inflammatory conditions, overlapping Artelo's ART27.13 (cancer cachexia) and ART26.12 (neuropathic pain) indications.
  • Anebulo Pharmaceuticals: Anebulo is an early-stage clinical company developing cannabinoid receptor modulators for intoxication and substance-use disorders, sharing Artelo's science platform around selective cannabinoid receptor targeting.
  • Sol-Gel Technologies: Sol-Gel is a dermatology-focused specialty pharmaceutical company developing topical treatments for inflammatory skin diseases including psoriasis, comparable to Artelo's ART26.12 psoriasis development pathway.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Artelo Biosciences social profiles

Digital presence

Artelo Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Artelo Biosciences leadership team

Management profile

Number of profiles

Profiles6 records

Artelo Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Artelo Biosciences funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Artelo Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Artelo Biosciences

What does Artelo Biosciences do?

Artelo Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of three drug candidates that modulate lipid-signaling pathways and the endocannabinoid system. The pipeline includes ART27.13 (dual CB1/CB2 receptor agonist for cancer anorexia-cachexia syndrome), ART26.12 (selective FABP5 inhibitor for chemotherapy-induced peripheral neuropathy and neuropathic pain), and ART12.11 (CBD:TMP cocrystal for anxiety and depression). The company has no commercial products and currently generates no product revenue.

Is Artelo Biosciences a public or private company?

Artelo Biosciences is a public company. It is classified as public and is currently operating.

When was Artelo Biosciences founded?

Artelo Biosciences was founded in 2017. It employs 11 to 50 people.

Where is Artelo Biosciences based?

Artelo Biosciences is headquartered in La Jolla, United States, in the North America region.

How does Artelo Biosciences make money?

One revenue line is on record: no Commercial Revenue.

Who are Artelo Biosciences's main competitors?

Direct peers on record are Corbus Pharmaceuticals, Botanix Pharmaceuticals, InMed Pharmaceuticals, Zynerba Pharmaceuticals and Skye Bioscience. Jazz Pharmaceuticals (GW Pharmaceuticals) is listed as a broad incumbent. Emerging players are Cara Therapeutics, Tetra Bio-Pharma, Anebulo Pharmaceuticals and Sol-Gel Technologies.

Does Artelo Biosciences have an API?

No public API is recorded for Artelo Biosciences.

What industry is Artelo Biosciences in?

Artelo Biosciences's product category is Clinical-stage Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeArtelo Biosciences surges after obesity patent filing puts ART27.13 in focus | ARTL Stock NewsArtelo Biosciences stock surged 207.2% after the company filed a provisional patent for ART27.13 in obesity, including use with GLP-1 drugs. The filing expanded on mouse data showing semaglutide-like weight loss as a standalone therapy and greater effects in combination, reigniting speculative interest.BioSpaceArtelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical FindingsArtelo Biosciences filed a provisional patent application for ART27.13 in obesity, covering monotherapy and combination with semaglutide. The DIO-2 study showed ART27.13 alone produced ~20% weight loss and with semaglutide ~40%, with 80% fat loss. The company plans to investigate mechanisms and pursue further development.Stock TitanArtelo Biosciences to Present at H.C. WainwrightArtelo Biosciences CEO Gregory D. Gorgas will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City on September 14-16, 2026. The presentation is available online on September 11, 2026, and management will hold one-on-one investor meetings during the conference.Seeking AlphaArtelo Biosciences announces 1-for-9 reverse stock split (ARTL:NASDAQ)Artelo Biosciences (NASDAQ: ARTL) announced on Thursday it will execute a 1-for-9 reverse stock split of its common stock, with trading beginning Aug. 31. Holders will receive whole shares with no fractional shares issued, and outstanding warrants and derivatives will adjust automatically. The company expects about 547,774 shares outstanding after the transaction.AInvestArtelo Biosciences - patent protection for ART27.13 expected through 2041Artelo Biosciences received a Notice of Allowance from the European Patent Office for its patent application covering the commercial formulation of ART27.13, extending protection through December 2041. This milestone secures long-term exclusivity for the drug in Europe while it undergoes Phase 2 clinical trials for cancer-related anorexia. The company continues to advance its pipeline and pursue a digital asset treasury strategy involving Solana.AInvestArtelo Biosciences - receives USPTO notice of allowance for ART27.13 formulation patentArtelo Biosciences received a notice of allowance from the USPTO for its ART27.13 formulation patent. This approval marks a significant regulatory milestone for the company's intellectual property portfolio regarding this specific formulation.GlobeNewswireArtelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 StudiesArtelo Biosciences received a USPTO Notice of Allowance for a patent on its lead drug ART27.13, covering the intended commercial formulation. The drug is in Phase 2 studies for cancer-related anorexia and glaucoma, with interim data showing weight gain in cancer patients. The patent is expected to extend protection through 2041.Stock TitanArtelo Biosciences Gets ART27.13 Notice of AllowanceArtelo Biosciences received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering the commercial formulation of its investigational drug ART27.13. This approval extends patent protection for the cannabinoid agonist, which is currently undergoing Phase 2 trials for cancer-related anorexia and glaucoma, through 2041. The milestone strengthens the company's intellectual property foundation as it advances the drug in clinical studies.BioSpaceArtelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial ResultsArtelo Biosciences reported Q2 2026 results with a net loss of $2.4 million and cash of $4.2 million. The company advanced its lead FABP5 inhibitor ART26.12 toward a Phase 1 multiple-dose study in Q4 2026, and ART27.13 showed weight gain in a Phase 2 cancer study. It also plans a Phase 1 study for its CBD:TMP cocrystal ART12.11.AInvestThe Real Story on Artelo Biosciences Isn't the Pipeline. It's the Runway.Artelo Biosciences reported $10.3 million in cash and cut debt during the first half of 2026, extending its financial runway through 2027 despite a $5.4 million net loss. The company has enrolled the first patient in its fully funded Phase 2 DREAM glaucoma study for ART27.13 and is advancing ART26.12 and ART12.11 through various clinical stages. Near-term survival depends on positive data readouts from these programs in late 2026 to attract partnerships or avoid dilutive financing.